Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity.
Neuropeptide Y (NPY) regulates cardiovascular function, smooth muscle contraction and smooth muscle cell proliferation. Stimulation of NPY Y1 and Y2 receptor subtypes has been shown to result in increases in second messengers, such as cytosolic calcium concentrations, which precede physiological events such as cell contraction. To assess whether NPY receptors also stimulate second messengers which may precede mitogenic effects, we measured the mitogen-activated protein kinase (MAPK) activity in NPY receptor-expressing cell lines in response to NPY. CHO K1 cells stably expressing either NPY Y1 or Y2 receptors were shown to specifically bind radiolabelled Peptide YY (PYY), and MAPK activity in these cells was assessed using a peptide kinase assay. NPY stimulated dose-dependent increases in MAPK activity in both NPY Y1 and Y2 receptor-expressing cell lines. The NPY-stimulated MAPK activity was sensitive to pretreatment with pertussis toxin, the MAPK specific inhibitor PD098059 or wortmannin, an inhibitor of phosphatidylinositol-3-kinase (PI-3-K). These results indicate that both NPY Y1 and Y2 receptors stimulate wortmannin-sensitive increases in MAPK activity via Gi proteins and suggest a role for NPY Y1 and Y2 receptors in the regulation of smooth muscle cell growth involved in hypertrophy.
Nie
M
M
Neurosciences and Molecular Pharmacology, School of Biomedical Sciences, Medical School, Nottingham, UK.
Selbie
L A
LA
D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006224:Cricetinae; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D024510:Muscle Development; D009131:Muscle, Smooth, Vascular / Q000254:growth & development / Q000378:metabolism; D009478:Neuropeptide Y / Q000378:metabolism / Q000494:pharmacology; D019894:Peptide YY / Q000378:metabolism; D037342:Pertussis Toxin; D000081082:Phosphoinositide-3 Kinase Inhibitors; D017476:Receptors, Neuropeptide Y / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D014162:Transfection; D010566:Virulence Factors, Bordetella / Q000494:pharmacology; D000077191:Wortmannin
D000730:Androstadienes; D004791:Enzyme Inhibitors; D005419:Flavonoids; D009478:Neuropeptide Y; D000081082:Phosphoinositide-3 Kinase Inhibitors; D017476:Receptors, Neuropeptide Y; D011994:Recombinant Proteins; D010566:Virulence Factors, Bordetella; C097212:neuropeptide Y-Y1 receptor; C095889:neuropeptide Y2 receptor; D019894:Peptide YY; D037342:Pertussis Toxin; D017871:Calcium-Calmodulin-Dependent Protein Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; D000077191:Wortmannin